Company: DVAX
Filing Date: 2025-04-04
Form Type: DEFA14A
Source: 0000930413-25-001154
Chunk: 2

Company: DYNAVAX TECHNOLOGIES CORP
Filing Date: 2025-04-04
Form: DEFA14A
Chunk 2
---
, as amended, and Section 21E of the Securities Exchange Act of
1934, as amended, which are subject to a number of risks and uncertainties. All statements that are not historical facts are forward-looking
statements. Forward-looking statements can generally be identified by the use of words such as “anticipate,” “believe,”
“continue,” “estimate,” “expect,” “intend,” “will,” “may,”
“plan,” “potential,” “seek,” “would” and similar expressions, or the negatives
thereof, or they may use future dates. Forward-looking statements made in this document include statements regarding the Company’s
plans to submit a declassification proposal at its 2025 Annual Meeting, expected contributions from newly appointed directors,
the planned resignation of certain directors, expectations regarding delivering value for our stockholders, our future growth,
market share, expected product revenue and long-term performance. Actual results may differ materially from those set forth in
this press release due to the risks and uncertainties inherent in our business, including, the risk that circumstances surrounding
or leading up to our 2025 Annual Meeting may change, risks relating to our ability to commercialize and supply HEPLISAV-B, and
risks related to the implementation of our long-term growth objectives, as well as other risks detailed in the “Risk Factors”
section of our Annual Report on Form 10-K for the financial year ended December 31, 2024 and any periodic filings made thereafter,
as well as discussions of potential risks, uncertainties and other important factors in our other filings with the U.S. Securities
and Exchange Commission. These forward-looking statements are made as of the date hereof, are qualified in their entirety by this
cautionary statement and we undertake no obligation to revise or update information herein to reflect events or circumstances in
the future, even if new information becomes available. Information on Dynavax’s website at www.dynavax.com is not incorporated
by reference in our current periodic reports with the SEC.

Important Additional Information and Where to Find It

On April 3, 2025, the Company filed a preliminary proxy statement
on Schedule 14A (the “Proxy Statement”) and form of accompanying GOLD proxy card with the U.S. Securities and Exchange
Commission (the “SEC”) in connection with its 2025 Annual Meeting and its solicitation of proxies for the Company’s
director nominees and for other matters to be voted on. The Proxy Statement is in preliminary form and the